Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany-based CureVac has begun Phase 2b clinical trial to assess CV9104 in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer patients new to chemo therapy.
Subscribe to our email newsletter
CV9104, the RNActive cancer vaccine, encodes antigens that are overexpressed in prostate cancer.
University of Tubingen, Germany, urology department medical director and the study coordinating investigator Arnulf Stenzl said, "This trial will validate the safety and investigate the clinical efficacy of CureVac’s first-in-class mRNA-based cancer vaccine technology, RNActive, in patients with metastatic castration refractory prostate cancer."
Overall survival is the primary endpoint of the double-blind, randomised study CV9104, which will enroll around 200 patients.
CureVac chief executive officer Ingmar Hoerr said the RNActive vaccines are shown to be safe and induce balanced humoral and cellular immune responses against multiple cancer antigens in a study of an mRNA vaccine.
"Because of the robust immune response induced by our mRNA vaccine, we expect CV9104 to yield significant clinical benefit for patients with advanced prostate cancer," Hoerr added.